Lenz Therapeutics announces FDA acceptance of NDA for LNZ100
LENZ Therapeutics (LENZ) announced that the U.S. Food and Drug Administration, FDA, has accepted the Company’s New Drug Application, NDA, ...
Monthly Prescribing Reference5h
Aceclidine-Based Eye Drop Under Review for Presbyopia
LNZ100 is a single-use, once-daily eye drop containing aceclidine, a small molecule acetylcholine receptor agonist that causes miosis.
bovnews14h
Why Did Neumora Therapeutics Inc (NMRA) Stock Surge 6.32% Last Week?
On Friday, Neumora Therapeutics Inc (NMRA) stock saw a decline, ending the day at $16.49 which represents a decrease of $-0.47 or -2.77% from the prior close of $16.96. The stock opened at $17 and ...
Why LENZ Therapeutics Stock Hit A New 52-Week High Today
Lenz Therapeutics shares hit a new 52-week high during Monday's session. The company announced the FDA accepted its new drug ...
LENZ Therapeutics Shares Rise After FDA Accepts Application for Potential Eye Condition Treatment
LENZ Therapeutics said the submission for the treatment of presbyopia is supported by the positive data results from a Phase 3 study. Aceclidine is a new chemical entity in the U.S. and isn't approved ...
FDA Accepts LENZ Therapeutics' NDA For LNZ100 To Treat Presbyopia
(RTTNews) - LENZ Therapeutics, Inc. (LENZ) Monday said that the Food and Drug Administration (FDA) has accepted the company's new drug application for LNZ100 for the treatment of presbyopia.
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a ...